BiotechTube

telbivudine/LDT600

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Compensated Chronic Hepatitis B

Conditions

Compensated Chronic Hepatitis B

Trial Timeline

Mar 1, 2009 → —

NCT ID
NCT00877149

About telbivudine/LDT600

telbivudine/LDT600 is a approved stage product being developed by Novartis for Compensated Chronic Hepatitis B. The current trial status is completed. This product is registered under clinical trial identifier NCT00877149. Target conditions include Compensated Chronic Hepatitis B.

What happened to similar drugs?

2 of 4 similar drugs in Compensated Chronic Hepatitis B were approved

Approved (2) Terminated (1) Active (2)
✅Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBVMerckApproved
✅Telbivudine/LDT600ANovartisApproved
🔄Aliskiren + PlaceboNovartisPhase 3
🔄Albutein 20%GrifolsPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00877149ApprovedCompleted

Competing Products

9 competing products in Compensated Chronic Hepatitis B

See all competitors
ProductCompanyStageHype Score
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
25
Mesenchymal Stem CellRohto PharmaceuticalPre-clinical
26
Mesenchymal stem cellRohto PharmaceuticalPhase 1/2
32
Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBVMerckApproved
39
Terlipressin acetate + Serelaxin (RLX030)NovartisPhase 2
35
Aliskiren + PlaceboNovartisPhase 3
40
Telbivudine/LDT600ANovartisApproved
35
BMS-986259Bristol Myers SquibbPhase 2
35
Albutein 20%GrifolsPhase 3
37